Could Poison Be the Cure for Refractory Cough?
For some patients with interstitial lung disease (ILD) and persistent cough, standard therapies may not offer relief. A new study presented at the American College of Chest Physicians (CHEST) 2024 Annual Meeting suggests that a traditional Chinese medicine might hold promise: semen strychni, a compound derived from the Strychnos nux-vomica L plant.
A Potent Poison with Therapeutic Potential
Semen strychni contains strychnine, a toxin famous for its association with mystery novelist Agatha Christie. However, in controlled doses, it has shown efficacy in treating various conditions, including musculoskeletal and autoimmune disorders like rheumatoid arthritis, myasthenia gravis, and amyotrophic lateral sclerosis.
Dr. Mingwan Su, from Guang’anmen Hospital and the China Academy of Chinese Medical Sciences in Beijing, led the study exploring semen strychni’s potential for treating refractory cough associated with idiopathic interstitial pneumonia with autoimmune features (IPAFs).
The Study: Semen Strychni vs. Standard Therapy
The retrospective study included 41 patients with IPAF-associated cough who received 300 mg/day of low-dose semen strychni orally for two weeks. These patients were compared to a control group of 41 individuals matched for age, sex, and disease course who received standard therapies.
The results showed a significant improvement in cough severity as measured by the visual analog scale (VAS). Patients treated with semen strychni experienced a greater reduction in VAS scores compared to the control group. Furthermore, patients in the semen strychni group reported a significant improvement in quality of life, as assessed by the Leicester Cough Questionnaire.
Safety and Future Directions
Despite containing a potent toxin, semen strychni appeared generally safe in this study, with no reports of serious adverse events. However, one case of muscle twitching was observed in the treatment group.
While the study offers encouraging results, experts acknowledge the need for further research to confirm these findings and establish optimal dosages and long-term safety profiles. Dr. Vijay Balasubramanian, clinical professor of medicine at the University of California San Francisco, emphasizes the importance of regulated studies to understand the compound’s pharmacokinetics and dose characteristics.
“It’s very frustrating to treat chronic cough, especially associated with fibrotic lung disease, and the extent to which researchers will go to find that one product that perhaps can make a difference is understandable,” said Dr. Andrew R. Berman, director of the Division of Pulmonary and Critical Care Medicine at Rutgers Health New Jersey Medical School.
**Stay Informed:** Learn more about lung health and the latest medical advancements by visiting reputable sources like the American Lung Association and the National Heart, Lung, and Blood Institute.